 |
TSO3 Makes a Sale to a Referral SiteMarch 2, 2006Québec City, March 2, 2006 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces a third firm sale of its 125L Ozone Sterilizer, this time to a North American referral site.“This account has had an opportunity to thoroughly evaluate the usefulness of the ozone sterilization process in its Central Sterilization department. Their purchase of the unit is a strong endorsement of the benefits they derive from using it,” said Ann Hewitt, Vice President of Sales and Marketing. “We selected our referral sites carefully to give us a cross section of all the varieties of hospitals in North America. While we don’t expect that all of them will convert to ownership, each of them has provided us with a different perspective on the positive impact of the 125L in a sterile processing department. This new customer has been particularly enthusiastic about the environmental impact of decreasing ethylene oxide usage, because it is so toxic.” More Information on the Referral Sites Program The TSO3 marketing strategy has been to build market acceptance by entering into agreements with North American hospitals, called “referral sites,” to showcase its new ozone-based process for sterilizing medical instruments. With this trial program, TSO3 is demonstrating the significant savings and numerous benefits of the ozone sterilization technological platform through referrals from satisfied customer. TSO3 believes that those satisfactory referrals will contribute to the company’s success with current and future clients for the 125L Ozone Sterilizer. About TSO3 TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in 1998. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat and moisture-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization by Health Canada and by the U.S. Food and Drug Administration (FDA). TSO3 has sold its first sterilizer in Q4 2005. TSO3 currently has 54 employees, 16 of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.- 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications and Investor Relations Phone: (418) 651-0003, Ext. 237 Email: ccote@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
